Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial
A US-based subsidiary of Japanese pharma giant Sumitomo is touting the mid-stage results of a schizophrenia drug they say offers a new way to treat the long-elusive disorder, potentially helping stem an entire set of symptoms that have gone unmitigated under current therapies.
In a Phase II study of 245 early stage schizophrenia patients, published today in the New England Journal of Medicine, those given a pill called SEP-363856 improved 17.2 points on average on the Positive and Negative Syndrome Scale used to assess schizophrenia symptoms. That compared to a 9.7 point improvement for the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.